Drug interactions
Mavacamten + Ticlopidine
Severity: Contraindicated
Mavacamten and Ticlopidine: contraindicated interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ticlopidine inhibits CYP2C19, which is the main route of mavacamten metabolism, and may raise its exposure. Excess mavacamten can reduce ejection fraction and lead to heart failure from systolic dysfunction. The labeling contraindicates moderate to strong CYP2C19 inhibitors.
What this interaction means in plain words
Mavacamten and Ticlopidine are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.
Mavacamten belongs to Cardiovascular; Ticlopidine belongs to Cardiovascular.
Why it happens
Inhibition of CYP2C19 by ticlopidine reduces mavacamten clearance.
What to do
Avoid the combination and choose an alternative antiplatelet drug if possible. If it cannot be avoided, monitor LVEF closely and consider mavacamten dose reduction or interruption.
What to ask your pharmacist
- Is there an alternative to one of these two medicines for me?
- If both are essential, who is monitoring me and how often?
- Which symptoms mean I should stop and seek help straight away?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Mavacamten and Ticlopidine, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Ticlopidine
Other interactions of Mavacamten
- Apalutamide + Mavacamten Contraindicated
- Carbamazepine + Mavacamten Contraindicated
- Clarithromycin + Mavacamten Contraindicated
- Dexlansoprazole + Mavacamten Contraindicated
- Efavirenz + Mavacamten Contraindicated
- Enzalutamide + Mavacamten Contraindicated
Frequently asked questions
Can I take Mavacamten with Ticlopidine?
MediHelp rates the interaction as contraindicated. Mavacamten and Ticlopidine are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Ticlopidine inhibits CYP2C19, which is the main route of mavacamten metabolism, and may raise its exposure. Excess mavacamten can reduce ejection fraction and lead to heart failure from systolic dysfunction. The labeling contraindicates moderate to strong CYP2C19 inhibitors.
How serious is the interaction between Mavacamten and Ticlopidine?
MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and choose an alternative antiplatelet drug if possible. If it cannot be avoided, monitor LVEF closely and consider mavacamten dose reduction or interruption.
What other medicines interact with Ticlopidine?
MediHelp also lists interactions of Ticlopidine with, for example, Abrocitinib, Acetylsalicylic acid, Apixaban. The full list is on the Ticlopidine page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
